Literature DB >> 7514675

Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.

M Robert-Guroff1, A Louie, M Myagkikh, F Michaels, M P Kieny, M E White-Scharf, B Potts, D Grogg, M S Reitz.   

Abstract

Neutralization of a chimeric human immunodeficiency virus (HIV) type 1, containing the V3 loop of the MN isolate substituted within the HXB2 envelope, was enhanced up to 20-fold compared with the HXB2 or MN parental isolates by human HIV-positive sera. MN V3 loop-specific monoclonal antibodies were better able to recognize the chimeric virus compared with MN, staining a greater percentage of infected cells and exhibiting slight increases in relative affinity with a concomitant increase in neutralization titer. Competition analysis revealed that enhanced neutralization by human HIV-positive sera of the chimera was attributable in some cases to better reactivity with the linear V3 loop epitope but in others to conformational loop epitopes or previously cryptic or poorly recognized epitopes outside the loop region. Mice primed with a vaccinia virus-chimeric envelope recombinant and boosted with gp160 developed a spectrum of antibodies different from that of mice similarly immunized with HXB2 or MN recombinants or that of naturally infected humans. The chimeric envelope elicited antibodies with enhanced binding to the native MN V3 loop; however, the sites seen by the BALB/c mice were not neutralizing epitopes. Nevertheless, similar to the observations made with use of human sera, the chimeric virus was more readily neutralized by all of the immune mouse sera, an effect apparently mediated by non-V3 loop epitopes. These studies illustrate that not only the V3 loop sequence and conformation but also its context within the viral envelope influence neutralization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514675      PMCID: PMC236848     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

Authors:  M E White-Scharf; B J Potts; L M Smith; K A Sokolowski; J R Rusche; S Silver
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

2.  Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker.

Authors:  F di Marzo Veronese; M S Reitz; G Gupta; M Robert-Guroff; C Boyer-Thompson; A Louie; R C Gallo; P Lusso
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

3.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism.

Authors:  N E Sharpless; W A O'Brien; E Verdin; C V Kufta; I S Chen; M Dubois-Dalcq
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.

Authors:  S Karwowska; M K Gorny; A Buchbinder; V Gianakakos; C Williams; T Fuerst; S Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

6.  An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.

Authors:  P J Klasse; J A McKeating; M Schutten; M S Reitz; M Robert-Guroff
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

7.  Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Authors:  M Robert-Guroff; K Aldrich; R Muldoon; T L Stern; G P Bansal; T J Matthews; P D Markham; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

8.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  3 in total

1.  Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.

Authors:  T L Stern; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

2.  An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.

Authors:  M Mamounas; D J Looney; R Talbott; F Wong-Staal
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

3.  Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.

Authors:  E Hogervorst; J de Jong; A van Wijk; M Bakker; M Valk; P Nara; J Goudsmit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.